Verastem Oncology

Edit info

Founded: 2010

Location: Needham, MA

Employee range: 50 - 200

Clinical stage: Clin2

Therapy area: NSCLC

Drug types: ONC

Lead product: Avutometinib

Funding: $85M stock Jun 2023; $85M stock Jan 2023

verastem.com

linkedin.com

job board

Business:

Drugs Targeting Cancer Stem Cells

Drug notes:

Also 5 additional trials combo with defactinib Clin2 multiple cancers, 5 additional trials Clin1/Clin2 multiple cancers (partners: Amgen, Mirati Therapeutics)

About:

Verastem Oncology is specializing in the development of targeted therapies for cancer treatment through the targeting of the RAS family of genes. Mutations in these genes drive highly aggressive, often recurring cancers. Their scientific focus revolves around identifying and developing small molecule inhibitors that selectively target pathways critical to tumor growth and survival. Verastem Oncology employs advanced translational medicine and biomarker-driven approaches to accelerate drug development and treatment strategies. By pioneering innovative therapies that aim to disrupt cancer progression at its roots, Verastem Oncology strives to improve outcomes for patients battling a wide range of cancers, offering new hope through rigorous scientific research and clinical innovation.